Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Change in Acquisitions & Divestments (2020)

Ensysce Biosciences (ENSC) has disclosed Change in Acquisitions & Divestments for 1 consecutive years, with $393379.0 as the latest value for Q4 2020.

  • On a quarterly basis, Change in Acquisitions & Divestments changed N/A to $393379.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $184.8 million, a N/A change, with the full-year FY2020 number at $184.8 million, up 1495.17% from a year prior.
  • Change in Acquisitions & Divestments was $393379.0 for Q4 2020 at Ensysce Biosciences, down from $48.1 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $136.3 million in Q1 2020 to a low of $393379.0 in Q4 2020.